{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T12:19:34Z","timestamp":1789129174239,"version":"build-2803163510"},"reference-count":43,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T00:00:00Z","timestamp":1742169600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.jtct.2025.02.025","type":"journal-article","created":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T16:34:48Z","timestamp":1741365288000},"page":"352.e1-352.e10","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Best Practices in Gene Therapy for Sickle Cell Disease and Transfusion-dependent \u03b2-Thalassemia"],"prefix":"10.1016","volume":"31","author":[{"given":"Haydar","family":"Frangoul","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Stults","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-8403-3721","authenticated-orcid":false,"given":"Katie","family":"Bruce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Domm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clinton","family":"Carroll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-2502-5887","authenticated-orcid":false,"given":"Shelby","family":"Aide","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgan","family":"Duckworth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Misty","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7301-2673","authenticated-orcid":false,"given":"Meghann","family":"McManus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jtct.2025.02.025_bib0001","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1056\/NEJMoa2031054","article-title":"CRISPR-Cas9 gene editing for sickle cell disease and \u03b2-thalassemia","volume":"384","author":"Frangoul","year":"2021","journal-title":"N Engl J Med"},{"issue":"9861","key":"10.1016\/j.jtct.2025.02.025_bib0002","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/S0140-6736(12)61229-X","article-title":"Global epidemiology of sickle haemoglobin in neonates: a contemporary geostatistical model-based map and population estimates","volume":"381","author":"Piel","year":"2013","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.jtct.2025.02.025_bib0003","doi-asserted-by":"crossref","first-page":"592","DOI":"10.3109\/07853890.2015.1091942","article-title":"Increasing prevalence of thalassemia in America: implications for primary care","volume":"47","author":"Sayani","year":"2015","journal-title":"Ann Med"},{"issue":"3s","key":"10.1016\/j.jtct.2025.02.025_bib0004","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1016\/j.annemergmed.2020.08.009","article-title":"Trends in sickle cell disease-related mortality in the United States, 1979 to 2017","volume":"76","author":"Payne","year":"2020","journal-title":"Ann Emerg Med"},{"issue":"6","key":"10.1016\/j.jtct.2025.02.025_bib0005","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1182\/blood-2018-10-880575","article-title":"Decreased median survival of adults with sickle cell disease after adjusting for left truncation bias: a pooled analysis","volume":"133","author":"DeBaun","year":"2019","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.jtct.2025.02.025_bib0006","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1002\/ajh.21905","article-title":"Health-related quality of life in adults with sickle cell disease (SCD): a report from the comprehensive sickle cell centers clinical trial consortium","volume":"86","author":"Dampier","year":"2011","journal-title":"Am J Hematol"},{"issue":"8","key":"10.1016\/j.jtct.2025.02.025_bib0007","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMra2021838","article-title":"\u03b2-thalassemias","volume":"384","author":"Taher","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2025.02.025_bib0008","doi-asserted-by":"crossref","first-page":"361","DOI":"10.2147\/IJGM.S257340","article-title":"Patient-reported outcomes and economic burden of adults with sickle cell disease in the United States: a systematic review","volume":"13","author":"Lee","year":"2020","journal-title":"Int J Gen Med"},{"key":"10.1016\/j.jtct.2025.02.025_bib0009","doi-asserted-by":"crossref","first-page":"18010","DOI":"10.1038\/nrdp.2018.10","article-title":"Sickle cell disease","volume":"4","author":"Kato","year":"2018","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"10.1016\/j.jtct.2025.02.025_bib0010","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1186\/s12955-018-1009-5","article-title":"Quality of life among caregivers of sickle cell disease patients: a cross sectional study","volume":"16","author":"Madani","year":"2018","journal-title":"Health Qual Life Outcomes"},{"issue":"1","key":"10.1016\/j.jtct.2025.02.025_bib0011","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1182\/hematology.2021000250","article-title":"Gene therapy for sickle cell disease: where we are now?","volume":"2021","author":"Kanter","year":"2021","journal-title":"Hematology"},{"issue":"2","key":"10.1016\/j.jtct.2025.02.025_bib0012","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1002\/ajh.27102","article-title":"Luspatercept stimulates erythropoiesis, increases iron utilization, and redistributes body iron in transfusion-dependent thalassemia","volume":"99","author":"Garbowski","year":"2024","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jtct.2025.02.025_bib0013","series-title":"Nicosia (Cyprus): Thalassaemia International Federation","article-title":"Guidelines for the management of non transfusion dependent thalassaemia (NTDT)","author":"Taher","year":"2013"},{"issue":"1","key":"10.1016\/j.jtct.2025.02.025_bib0014","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1517\/17425255.2012.640674","article-title":"Deferasirox: pharmacokinetics and clinical experience","volume":"8","author":"Galanello","year":"2012","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"5","key":"10.1016\/j.jtct.2025.02.025_bib0015","first-page":"565","article-title":"Pulmonary syndrome in patients with thalassemia major receiving intravenous deferoxamine infusions","volume":"144","author":"Freedman","year":"1990","journal-title":"Am J Dis Child"},{"key":"10.1016\/j.jtct.2025.02.025_bib0016","series-title":"Cardiovascular Magnetic Resonance","first-page":"400","article-title":"33 - cardiac iron loading and myocardial T2*","author":"Westwood","year":"2019"},{"issue":"4","key":"10.1016\/j.jtct.2025.02.025_bib0017","first-page":"411","article-title":"An update on iron chelation therapy","volume":"10","author":"Poggiali","year":"2012","journal-title":"Blood Transfus"},{"issue":"3","key":"10.1016\/j.jtct.2025.02.025_bib0018","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1002\/ajh.27164","article-title":"Defining curative endpoints for sickle cell disease in the era of gene therapy and gene editing","volume":"99","author":"Locatelli","year":"2024","journal-title":"Am J Hematol"},{"issue":"5","key":"10.1016\/j.jtct.2025.02.025_bib0019","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1182\/blood-2011-01-332510","article-title":"Allogeneic hematopoietic stem cell transplantation for sickle cell disease: the time is now","volume":"118","author":"Hsieh","year":"2011","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jtct.2025.02.025_bib0020","doi-asserted-by":"crossref","first-page":"10838","DOI":"10.1038\/s41598-021-90405-1","article-title":"Cost-effectiveness of a hypothetical cell or gene therapy cure for sickle cell disease","volume":"11","author":"Salcedo","year":"2021","journal-title":"Scientific Reports"},{"issue":"4","key":"10.1016\/j.jtct.2025.02.025_bib0021","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.bbmt.2017.01.009","volume":"23","author":"Shenoy","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"18","key":"10.1016\/j.jtct.2025.02.025_bib0022","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1056\/NEJMoa2309676","article-title":"Exagamglogene autotemcel for severe sickle cell disease","volume":"390","author":"Frangoul","year":"2024","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jtct.2025.02.025_bib0023","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/ajh.26741","article-title":"Lovo-cel gene therapy for sickle cell disease: treatment process evolution and outcomes in the initial groups of the HGB-206 study","volume":"98","author":"Kanter","year":"2023","journal-title":"Am J Hematol"},{"issue":"5","key":"10.1016\/j.jtct.2025.02.025_bib0024","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1056\/NEJMoa2113206","article-title":"Betibeglogene autotemcel gene therapy for Non-beta(0)\/beta(0) Genotype beta-thalassemia","volume":"386","author":"Locatelli","year":"2022","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jtct.2025.02.025_bib0025","doi-asserted-by":"crossref","first-page":"5850","DOI":"10.1038\/s41467-023-40923-5","article-title":"Genetic reversal of the globin switch concurrently modulates both fetal and sickle hemoglobin and reduces red cell sickling","volume":"14","author":"De Souza","year":"2023","journal-title":"Nat Commun"},{"issue":"Supplement 1","key":"10.1016\/j.jtct.2025.02.025_bib0026","doi-asserted-by":"crossref","first-page":"4996","DOI":"10.1182\/blood-2023-187397","article-title":"AsCas12a gene editing of HBG1\/2 promoters with EDIT-301 results in rapid and sustained normalization of hemoglobin and increased fetal hemoglobin in patients with severe sickle cell disease and transfusion-dependent beta-thalassemia","volume":"142","author":"Hanna","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2025.02.025_bib0027","series-title":"Applied Base Editing to Treat BetaHemoglobinopathies","author":"Gaudelli","year":"2021"},{"issue":"7","key":"10.1016\/j.jtct.2025.02.025_bib0028","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1097\/MPH.0b013e31806451ac","article-title":"Children with sickle cell disease: growth and gonadal function after hematopoietic stem cell transplantation","volume":"29","author":"Brachet","year":"2007","journal-title":"J Pediatr Hematol Oncol"},{"issue":"2","key":"10.1016\/j.jtct.2025.02.025_bib0029","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/jca.22043","article-title":"Guidelines on the use of therapeutic apheresis in clinical practice - evidence-based approach from the writing committee of The American Society for Apheresis: the ninth special issue","volume":"38","author":"Connelly-Smith","year":"2023","journal-title":"J Clin Apher"},{"issue":"2","key":"10.1016\/j.jtct.2025.02.025_bib0030","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/tme.12205","article-title":"Guideline on the clinical use of apheresis procedures for the treatment of patients and collection of cellular therapy products. British Committee for standards in haematology","volume":"25","author":"Howell","year":"2015","journal-title":"Transfus Med"},{"issue":"19","key":"10.1016\/j.jtct.2025.02.025_bib0031","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1182\/bloodadvances.2018016725","article-title":"Successful hematopoietic stem cell mobilization and apheresis collection using plerixafor alone in sickle cell patients","volume":"2","author":"Esrick","year":"2018","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.jtct.2025.02.025_bib0032","doi-asserted-by":"crossref","DOI":"10.1016\/j.transci.2021.103059","article-title":"Parameters affecting successful stem cell collections for genetic therapies in sickle cell disease","volume":"60","author":"Justus","year":"2021","journal-title":"Transfus Apher Sci"},{"key":"10.1016\/j.jtct.2025.02.025_bib0033","article-title":"suspension for intravenous infusion: highlights of prescribing information","year":"2023","journal-title":"Vertex Pharmaceuticals Incorporated"},{"key":"10.1016\/j.jtct.2025.02.025_bib0034","series-title":"LYFGENIA\u00ae (lovotibeglogene autotemcel) suspension for intravenous infusion: Highlights of prescribing information","year":"2023"},{"issue":"4","key":"10.1016\/j.jtct.2025.02.025_bib0035","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1111\/bjh.18311","article-title":"Optimizing haematopoietic stem and progenitor cell apheresis collection from plerixafor-mobilized patients with sickle cell disease","volume":"198","author":"Sharma","year":"2022","journal-title":"British Journal of Haematology"},{"issue":"10","key":"10.1016\/j.jtct.2025.02.025_bib0036","doi-asserted-by":"crossref","first-page":"e497","DOI":"10.3324\/haematol.2019.236182","article-title":"Safe and efficient peripheral blood stem cell collection in patients with sickle cell disease using plerixafor","volume":"105","author":"Uchida","year":"2020","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.jtct.2025.02.025_bib0037","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.transci.2018.09.009","article-title":"Current state of apheresis technology and its applications","volume":"57","author":"Maitta","year":"2018","journal-title":"Transfus Apher Sci"},{"issue":"21","key":"10.1016\/j.jtct.2025.02.025_bib0038","doi-asserted-by":"crossref","first-page":"6867","DOI":"10.1158\/1078-0432.CCR-11-0074","article-title":"Population pharmacokinetics of busulfan in children: increased evidence for body surface area and allometric body weight dosing of busulfan in children","volume":"17","author":"Trame","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.jtct.2025.02.025_bib0039","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/bmt.2010.60","article-title":"Safety and efficacy of targeted busulfan therapy in children undergoing myeloablative matched sibling donor BMT for sickle cell disease","volume":"46","author":"McPherson","year":"2011","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"10.1016\/j.jtct.2025.02.025_bib0040","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/bmt.2013.152","article-title":"Hematopoietic SCT with cryopreserved grafts: adverse reactions after transplantation and cryoprotectant removal before infusion","volume":"49","author":"Shu","year":"2014","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"10.1016\/j.jtct.2025.02.025_bib0041","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/bjh.14727","article-title":"Earlier defibrotide initiation post-diagnosis of veno-occlusive disease\/sinusoidal obstruction syndrome improves Day +100 survival following haematopoietic stem cell transplantation","volume":"178","author":"Richardson","year":"2017","journal-title":"Br J Haematol"},{"issue":"10","key":"10.1016\/j.jtct.2025.02.025_bib0042","doi-asserted-by":"crossref","first-page":"e27269","DOI":"10.1002\/pbc.27269","article-title":"Defibrotide for the treatment of hepatic veno-occlusive disease\/sinusoidal obstruction syndrome following nontransplant-associated chemotherapy: Final results from a post hoc analysis of data from an expanded-access program","volume":"65","author":"Kernan","year":"2018","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.jtct.2025.02.025_bib0043","series-title":"Exploring Novel Clinical Trial Designs for Gene-Based Therapies: Proceedings of a Workshop","article-title":"The national academies collection: reports funded by national institutes of health","author":"Medicine","year":"2020"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636725010619?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636725010619?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T20:04:31Z","timestamp":1751400271000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636725010619"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":43,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S2666636725010619"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2025.02.025","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Best Practices in Gene Therapy for Sickle Cell Disease and Transfusion-dependent \u03b2-Thalassemia","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2025.02.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of The American Society for Transplantation and Cellular Therapy.","name":"copyright","label":"Copyright"}]}}